Purple Biotech says USPTO issues notice of allowance for CAPTN-3 tri-specific antibody patent application

PUBT · 2d ago
Purple Biotech says USPTO issues notice of allowance for CAPTN-3 tri-specific antibody patent application
  • Purple Biotech received a USPTO Notice of Allowance for a U.S. patent application covering tri-specific antibody constructs and methods of use.
  • The allowance expands IP protection for the CAPTN-3 platform, a modular backbone for conditionally activated multispecific antibodies.
  • Patent protection targets faster development of new antibody candidates by swapping tumor-associated antigen binding domains on a common architecture.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Purple Biotech Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609020730PRIMZONEFULLFEED9819870) on September 02, 2026, and is solely responsible for the information contained therein.